| Title |
Dendritic cell vaccines for high-grade gliomas
|
|---|---|
| Published in |
Therapeutics and Clinical Risk Management, July 2018
|
| DOI | 10.2147/tcrm.s135865 |
| Pubmed ID | |
| Authors |
Matthew E Eagles, Farshad Nassiri, Jetan H Badhiwala, Suganth Suppiah, Saleh A Almenawer, Gelareh Zadeh, Kenneth D Aldape |
| Abstract |
Glioblastoma (GBM) is the most common and fatal primary adult brain tumor. To date, various promising chemotherapeutic regimens have been trialed for use in GBM; however, temozolomide (TMZ) therapy remains the only US Food and Drug Administration-approved first-line chemotherapeutic option for newly diagnosed GBM. Despite maximal therapy with surgery and combined concurrent chemoradiation and adjuvant TMZ therapy, the median overall survival remains approximately 14 months. Given the failure of conventional chemotherapeutic strategies in GBM, there has been renewed interest in the role of immunotherapy in GBM. Dendritic cells are immune antigen-presenting cells that play a role in both the innate and adaptive immune system, thereby making them prime vehicles for immunotherapy via dendritic cell vaccinations (DCVs) in various cancers. There is great enthusiasm surrounding the use of DCVs for GBM with multiple ongoing trials. In this review, we comprehensively summarize the safety, efficacy, and quality of life results from 33 trials reporting on DCV for high-grade gliomas. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 50% |
| United Kingdom | 1 | 25% |
| Unknown | 1 | 25% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 50% |
| Science communicators (journalists, bloggers, editors) | 1 | 25% |
| Practitioners (doctors, other healthcare professionals) | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 80 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 80 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 16 | 20% |
| Student > Master | 12 | 15% |
| Other | 6 | 8% |
| Unspecified | 6 | 8% |
| Student > Postgraduate | 6 | 8% |
| Other | 17 | 21% |
| Unknown | 17 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 19 | 24% |
| Biochemistry, Genetics and Molecular Biology | 9 | 11% |
| Immunology and Microbiology | 8 | 10% |
| Unspecified | 6 | 8% |
| Neuroscience | 5 | 6% |
| Other | 7 | 9% |
| Unknown | 26 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 October 2018.
All research outputs
#14,393,794
of 25,385,509 outputs
Outputs from Therapeutics and Clinical Risk Management
#591
of 1,323 outputs
Outputs of similar age
#167,137
of 341,606 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#19
of 31 outputs
Altmetric has tracked 25,385,509 research outputs across all sources so far. This one is in the 42nd percentile – i.e., 42% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,323 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one has gotten more attention than average, scoring higher than 54% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 341,606 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.
We're also able to compare this research output to 31 others from the same source and published within six weeks on either side of this one. This one is in the 38th percentile – i.e., 38% of its contemporaries scored the same or lower than it.